Agenus | AGEN - Current Liabilities


Agenus reported $231.82M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Agenus USD 231.82M 17.42M Jun/2026
Amgen USD 23.23B 2.27B Sep/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Celldex Therapeutics USD 60.52M 808K Sep/2026
CSL USD 4.61B 207M Dec/2025
Eli Lilly USD 47B 745M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Glaxosmithkline GBP 20.72B 1.71B Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Intrexon USD 23.02M 38K Jun/2024
J&J USD 55.46B 562M Sep/2026
Jiangsu Hengrui CNY 6.9B 2.65B Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merck EUR 8.12B 1.22B Jun/2026
Merck USD 28.8B 1.07B Sep/2026
Northwest Biotherapeutics USD 82.97M 4.93M Mar/2026
Novartis USD 32.52B 777M Sep/2026
Novavax USD 329.84M 729K Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 84.21M 21.47M Sep/2026